CBS 2019
CBSMD教育中心
English

DAPT Duration

科研文章

荐读文献

State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting - A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation

Clinical Trial2010 Nov;340(5):356-9.

JOURNAL:Am J Med Sci. Article Link

Respiratory syncytial virus infection and risk of acute myocardial infarction

Guan XR, Jiang LX, Ma XH et al. Keywords: Respiratory syncytial virus, Infection, Acute myocardial infarction

ABSTRACT


INTRODUCTION - Increasing evidences have shown that pathogens may promote atherosclerosis and trigger acute myocardial infarction (AMI). There is no report on the association between respiratory syncytial virus (RSV) infection and AMI. The case-control study was used to assess the association of previous RSV infection and acute myocardial infarction.


METHODS - AMI cases and non-AMI controls were recruited from patients at a large teaching hospital in Harbin, China, during October 1, 2005, to March 31, 2006, and October 1, 2006, to March 31, 2007. Questionnaire survey was conducted to collect information on demographic characteristics and heart disease risk factors. Fasting blood sample was obtained to measure immunoglobulin G antibodies to RSV, Cytomegalovirus, herpes simplex virus type-1 and type-2, adenovirus, Rubella virus, Chlamydia pneumoniae and Helicobacter pylori and to measure the level of cholesterol, fasting serum glucose, triglycerides and high-sensitivity C-reactive protein.

RESULTS - AMI group had more smokers than controls (56.9% versus 18.0%) and were more likely to have positive immunoglobulin G antibodies to RSV (OR, 6.2; 95% CI, 3.5-10.7; P < 0.001). After adjustment for potential confounding variables, the association between RSV and AMI remained (adjusted odds ratio, 11.1; 95% confidence interval, 3.3-29.5).

CONCLUSIONS - Our study supported the hypothesis that the previous RSV infection was associated with AMI. This indicates that prevention and proper treatment of RSV infection are of great clinical importance for the reduction of AMI risk.